Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers the Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
It also provides the Accelerate PhenoTest BC Kit, a test kit for the system, which is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
In addition, the company offers the Accelerate Arc system, an instrument and associated one-time-use test kit that automates the clean-up and concentration of microbial cells from positive blood culture samples. Further, it develops the Accelerate WAVE system, which performs AST directly from positive blood culture bottles and bacterial isolate colonies to report minimum inhibitory concentrations.
The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
On May 8, 2025, Accelerate Diagnostics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
